UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Company Overview - UroGen Pharma Ltd. is a biotech company focused on developing and commercializing innovative solutions for urothelial and specialty cancers [4] - The company has developed RTGel, a proprietary sustained-release hydrogel-based platform technology aimed at improving therapeutic profiles of existing drugs [4] - UroGen's first commercial product treats low-grade upper tract urothelial cancer, while its second product is the first FDA-approved medication for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer [4] Recent Developments - UroGen announced the grant of inducement restricted stock units (RSUs) to 40 new employees to support the commercialization of its approved products Jelmyto and ZUSDURI™ [1] - A total of up to 67,700 ordinary shares are issuable upon the vesting and settlement of the RSUs, which will vest equally over three years [2] - The RSUs were granted as an inducement material to each employee entering employment with UroGen, in accordance with Nasdaq Listing Rule 5635(c)(4) [3]